

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEGEND STRATEGY INTERNATIONAL HOLDINGS GROUP COMPANY LIMITED

枋濬國際集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1355)

**SUPPLEMENTAL ANNOUNCEMENT ON
DISCLOSEABLE TRANSACTION
IN RELATION TO
THE ACQUISITION OF SHARES IN
AURO HONG KONG LIMITED**

Reference is made to the announcement of Legend Strategy International Holdings Group Company Limited (the “**Company**”) dated 23 December 2025 (the “**Announcement**”) in relation to, among other things, the Acquisition constituting a discloseable transaction for the Company. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcements. In addition to the information provided in the Announcement, the Board would like to provide the following additional information regarding the disclosure with respect to the Acquisition.

BUSINESS MODEL AND REVENUE OF BEISHENG BIOTECHNOLOGY GROUP

Business Model

Beisheng Biotechnology's core business model is to provide higher-quality, more convenient, and lower-cost industry infrastructure services for DNA/strain manufacturing and related data production services through:- (i) design software (Tosycon®) sales and subscription; (ii) vector and target organism (microbes, reagents, cell lines, plant strains, animal individuals, etc.) manufacturing and sales; (iii) provision of consultations and solutions services using its self-established bio-manufacturing standard (ArchiCel®).

The core competitive advantages of Beisheng Biotechnology's integrated infrastructure platform are:

- (i) Design software (Tosycon®) integrated with the manufacturing platform, reducing supplies costs and improving technology utilization efficiency.

The design-end software developed by Beisheng Biotechnology directly connects design and manufacturing, outsmarting traditional design software that segregate design and subsequent acquisition of raw material elements by having to go through laborious process of acquisition from various traditional biotechnology infrastructure suppliers. This direct-to-customer model saves users the time cost of decomposing material elements and sourcing from different suppliers.

- (ii) Turnkey, self-developed industrial-grade manufacturing system, vector and target organism for clients, reducing production costs and increasing efficiency.
- (iii) Through its self-established bio-manufacturing standard (ArchiCel®), Beisheng Biotechnology has innovatively achieved an optimisation of design and manufacturing. This allows a reduction of workload of clients' senior R&D personnel, enabling more efficient design work and also lower the entry barrier of senior R&D personnel as senior R&D personnel no longer required to acquire skills on manufacturing.

Revenue

The revenue of Beisheng Biotechnology Group:–

	For the year ended 31 December 2023 (RMB'000) (unaudited)	For the year ended 31 December 2024 (RMB'000) (unaudited)	For the eleven months ended 30 November 2025 (RMB'000) (unaudited)
Sales of beer	675.5	496.9	–
Provision of services, design software sales and subscription	808.1	2,169.4	78.3
Sales of vector and target organism (including reagent and laboratory material)	327.6	1,279.0	122.8
Rental income on lease of plant and equipment to Yanwu	–	–	285.6
	<u>1,811.2</u>	<u>3,945.3</u>	<u>486.7</u>

The major customers of Beisheng Biotechnology Group ranged from local businesses in the PRC to multi-national global enterprises. The business nature of customers of Beisheng Biotechnology Group include agricultural trader and processor, biotechnology enterprise, alcoholic beverage enterprise, high-tech biomedical enterprise and laboratory technical service enterprise.

In 2023 and 2024, Beisheng Biotechnology began to trial run its design software, vector and strain architecture technology, and process-supporting reagent R&D and production technology to sell, at the pre-commercial stage, beer, vector and target organism (including reagent) at a small and controlled scale and to provide limited scope of services in order to testify and refine the technological and economic feasibility of its business model. In 2025, Beisheng Biotechnology reduced the pre-commercial sales and focused on fine tuning and adjusting its improving its bioinformatics software (Tosycon®) and its own proprietary, industry-first standard architecture for vectors and strains (ArchiCel®) to gear up for the full launch of its products and services in 2026, thus leading to a decrease in revenue.

Following the initial success of production and sale at the pre-commercial stage, beer (through a third party producer using Beisheng Biotechnology’s fermentation technology) and reagent at a small and controlled scale and to provide limited scope of services by Beisheng Biotechnology in order to testify and refine the technological and economic feasibility of its business model in 2023 and 2024, Beisheng Biotechnology establishes and currently holds 20% equity interest in the associate, 衍物通造(中山) 科技有限公司, or transliterated as Yanwu Tongzao (Zhongshan) Technology Co., Ltd. (“**Yanwu**”), to further implement and enhance its fermentation production capabilities.

The main business of Yanwu is the production and sales of alcoholic beverages, soft drinks, and food using proprietary fermentation technology developed by Beisheng Biotechnology.

MANAGEMENT OF THE ACQUISITION BY THE GROUP

The Group currently has engaged over 10 management staff and independent consultants to assist, covering areas of R&D, marketing, production and quality control, using synthetic biology, bio-manufacturing technologies, in the healthcare and beauty business segment. The management staff and independent consultants all have over 5 years of relevant experience and have bachelor degree or above on relevant disciplines such as biomedicine, engineering and management.

In particular, the head of R&D of the Group has accumulated over 10 years of research and development experience in the healthcare and beauty industry. The head of R&D has the experience of completing the compilation of medical device design and development process documents and revised design and development control procedure documents. The head of R&D also has led the design and development of collagen dressing projects, completing key tasks such as formula optimization, stability studies, biological evaluation, and clinical trial initiation in her previous employment.

In particular, the head of production of the Group is a licensed pharmacist, the head of production has accumulated over 20 years of production management experience in the healthcare and beauty industry.

Accordingly, the Group expects that its team has the requisite knowledge and management experience to collaborate with and monitor operation of Beisheng Biotechnology upon completion of the Acquisition. Upon completion of the Acquisition, the Group will be able to nominate and replace up to 2 directors to the current board of directors of Beisheng Biotechnology, made up of 5 members. The 2 directors to be appointed by the Group will monitor the daily operations of the Beisheng Biotechnology Group and report to the Group on a monthly + ad hoc basis.

FUNDING OF THE ACQUISITION BY THE GROUP

The Group funded the first payment of HK\$15,000,000 of the Consideration from interest-free borrowings from Osibao Cosmetics International Limited which currently holds 28.99% equity interest in the Company. Osibao Cosmetics International Limited also agrees to fund the balance of the Consideration of HK\$7,000,000 by interest-free fundings.

Currently, Beisheng Biotechnology has no specific future funding requirements and the Group has no commitment or obligation for additional fundings under the Acquisition.

This announcement is supplemental to and should be read in conjunction with the Announcement. Save as disclosed above, the Board confirms that the above supplemental information does not affect other information contained in the Announcement and the content of the Announcement remains correct and unchanged.

Shareholders and potential investors of the Company should note that the Completion is subject to the fulfillment of the conditions precedent under the Sale and Purchase Agreement. As the Acquisition may or may not proceed, Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the securities of the Company.

By Order of the Board
Legend Strategy International Holdings Group Company Limited
Lee Tsz Yan
Executive Director

Hong Kong, 3 March 2026

As at the date of this announcement, the Board comprises:

Executive Director:

Ms. Lee Tsz Yan

Non-executive Directors:

Mr. Cheung Ching Mo

Mr. Hu Xinglong

Independent non-executive Directors:

Mr. Wu Jilin

Mr. Lam Cheung Shing Richard

Mr. So Yin Wai